| Style | Citing Format |
|---|---|
| MLA | Mirmosayyeb O, et al.. "Safety and Efficacy of Covid-19 Vaccines Among Patients With Multiple Sclerosis: Letter to Editor." International Journal of Preventive Medicine, vol. 15, no. , 2024, pp. -. |
| APA | Mirmosayyeb O, Ghaffary EM, Zabeti A, Shaygannejad V (2024). Safety and Efficacy of Covid-19 Vaccines Among Patients With Multiple Sclerosis: Letter to Editor. International Journal of Preventive Medicine, 15(), -. |
| Chicago | Mirmosayyeb O, Ghaffary EM, Zabeti A, Shaygannejad V. "Safety and Efficacy of Covid-19 Vaccines Among Patients With Multiple Sclerosis: Letter to Editor." International Journal of Preventive Medicine 15, no. (2024): -. |
| Harvard | Mirmosayyeb O et al. (2024) 'Safety and Efficacy of Covid-19 Vaccines Among Patients With Multiple Sclerosis: Letter to Editor', International Journal of Preventive Medicine, 15(), pp. -. |
| Vancouver | Mirmosayyeb O, Ghaffary EM, Zabeti A, Shaygannejad V. Safety and Efficacy of Covid-19 Vaccines Among Patients With Multiple Sclerosis: Letter to Editor. International Journal of Preventive Medicine. 2024;15():-. |
| BibTex | @article{ author = {Mirmosayyeb O and Ghaffary EM and Zabeti A and Shaygannejad V}, title = {Safety and Efficacy of Covid-19 Vaccines Among Patients With Multiple Sclerosis: Letter to Editor}, journal = {International Journal of Preventive Medicine}, volume = {15}, number = {}, pages = {-}, year = {2024} } |
| RIS | TY - JOUR AU - Mirmosayyeb O AU - Ghaffary EM AU - Zabeti A AU - Shaygannejad V TI - Safety and Efficacy of Covid-19 Vaccines Among Patients With Multiple Sclerosis: Letter to Editor JO - International Journal of Preventive Medicine VL - 15 IS - SP - EP - PY - 2024 ER - |